Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

140 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
Pagan V, Ceron L, Paccagnella A, Pizzi G. Pagan V, et al. J Cardiovasc Surg (Torino). 2006 Oct;47(5):595-601. J Cardiovasc Surg (Torino). 2006. PMID: 17033611
The purpose of this study is to evaluate prospectively the reproducibility of the trimodality treatment results in a patient population with mesothelioma staged by the IMIG classification. ...The restricted group of patients with epithelial, N0-1, completely resected MPM ( …
The purpose of this study is to evaluate prospectively the reproducibility of the trimodality treatment results in a patient populati …
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Ardizzoni A, et al. J Natl Cancer Inst. 2007 Jun 6;99(11):847-57. doi: 10.1093/jnci/djk196. J Natl Cancer Inst. 2007. PMID: 17551145
A general variance-based method was used to estimate the summary hazard ratios (HRs), odds ratios (ORs), and their 95% confidence intervals (CIs) for mortality, objective response, and toxicity. ...A random-effects model that takes into account interstudy variation
A general variance-based method was used to estimate the summary hazard ratios (HRs), odds ratios (ORs), and their 95% confidence int
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M, Rossi F, Fila G. Ghi MG, et al. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7. doi: 10.1016/j.ijrobp.2003.10.055. Int J Radiat Oncol Biol Phys. 2004. PMID: 15145166 Clinical Trial.
The stage distribution was as follows: Stage II, 1 patient; Stage III, 6 patients; and Stage IV, 17; 18 patients had a performance status of 0 and 6 had a performance status of 1. ...A randomized multicenter Phase III study has been started with the aim of co …
The stage distribution was as follows: Stage II, 1 patient; Stage III, 6 patients; and Stage IV, 17; 18 patients had a performance st …
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V; GSTVP (Gruppo di Studio Tumori Polmonari del Veneto). Paccagnella A, et al. Lung Cancer. 2004 Jan;43(1):83-91. doi: 10.1016/s0169-5002(03)00280-0. Lung Cancer. 2004. PMID: 14698542 Clinical Trial.
However, we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39). ...A carboplatin containing regimen with better toxicity …
However, we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10. …
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L, Monfardini S. Favaretto AG, et al. Cancer. 2003 Jun 1;97(11):2791-7. doi: 10.1002/cncr.11405. Cancer. 2003. PMID: 12767092 Clinical Trial.
Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated. ...Minor adjustments in schedule (3-week cycles instead of 4-week cycle …
Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival o …
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Paccagnella A, Mastromauro C, D'Amanzo P, Ghi MG. Paccagnella A, et al. Oncologist. 2010;15 Suppl 3:8-12. doi: 10.1634/theoncologist.2010-S3-08. Oncologist. 2010. PMID: 21036883 Clinical Trial.
A modest but significant improvement in survival has been observed with cisplatin and 5-fluorouracil (PF) induction before radiotherapy over that seen with radiotherapy alone. ...A median overall survival time of 33.3 months and a 1-year survival rate of 78%
A modest but significant improvement in survival has been observed with cisplatin and 5-fluorouracil (PF) induction before radiothera
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Paccagnella A, Oniga F, Bearz A, Favaretto A, Clerici M, Barbieri F, Riccardi A, Chella A, Tirelli U, Ceresoli G, Tumolo S, Ridolfi R, Biason R, Nicoletto MO, Belloni P, Veglia F, Ghi MG. Paccagnella A, et al. J Clin Oncol. 2006 Feb 1;24(4):681-7. doi: 10.1200/JCO.2005.03.2722. J Clin Oncol. 2006. PMID: 16446341 Clinical Trial.
No triplet novel agent combination has until now shown superiority over a two-drug combination for advanced NSCLC. We therefore conducted a clinical trial to test if paclitaxel/carboplatin/gemcitabine (PCG) increases overall survival (OS) and response rate (RR) over …
No triplet novel agent combination has until now shown superiority over a two-drug combination for advanced NSCLC. We therefore condu …
Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up.
Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, Boldrin F, Marchiori C, Lunghi F, Fede A, Bordin A, Da Mosto MC, Sileni VC, Orlando A, Jirillo A, Tomio L, Pappagallo GL, Ghi MG. Zorat PL, et al. J Natl Cancer Inst. 2004 Nov 17;96(22):1714-7. doi: 10.1093/jnci/djh306. J Natl Cancer Inst. 2004. PMID: 15547184 Clinical Trial.
A total of 237 patients with nonmetastatic stage III or IV head and neck carcinoma were randomly assigned to receive four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) or locoregional treatment alone (group B). ...Among operable pat
A total of 237 patients with nonmetastatic stage III or IV head and neck carcinoma were randomly assigned to receive four cycles of n
Long term results of surgery and chemotherapy in small cell lung cancer.
Rea F, Callegaro D, Favaretto A, Loy M, Paccagnella A, Fantoni U, Festi G, Sartori F. Rea F, et al. Eur J Cardiothorac Surg. 1998 Oct;14(4):398-402. doi: 10.1016/s1010-7940(98)00203-6. Eur J Cardiothorac Surg. 1998. PMID: 9845145
OBJECTIVE: The aim of the study is to analyse long-term results of patients with small cell lung cancer (SCLC) treated at the same institution according to a prospective study including surgery, chemotherapy, and radiotherapy. ...Fifty-one patients (49%) had a relap …
OBJECTIVE: The aim of the study is to analyse long-term results of patients with small cell lung cancer (SCLC) treated at the same instituti …
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Favaretto A, Ceresoli GL, Paccagnella A, Barbieri F, Bearz A, Ghiotto C, Oniga F, Schiavon S, Frustaci S, Villa E. Favaretto A, et al. Ann Oncol. 2000 Nov;11(11):1421-6. doi: 10.1023/a:1026527004596. Ann Oncol. 2000. PMID: 11142482 Clinical Trial.
We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination. A phase II study was subsequently conducted to evaluate the activity and toxicity of PCG. ...CONCLUSIONS: PCG is a promising regimen for treating advanced NSCLC. A
We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination. A phase II study was subsequently …
140 results
Jump to page
Feedback